Clinical Trials
38 trialsNCT01288911 2024-12-06
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT01969578 2024-11-05
Androgen Deprivation Therapy in Advanced Salivary Gland Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00866554 2023-06-02
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
CHU de Quebec-Universite Laval
Phase 2 Completed
NCT02058706 2023-05-10
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT03043807 2023-02-16
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02716974 2022-08-04
oligo-mets
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00468715 2022-08-03
Bicalutamide in Treating Patients With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02614859 2022-03-29
BIMET-1
Fox Chase Cancer Center
Phase 2 Completed
NCT02059213 2020-09-16
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02697032 2019-11-27
FDHT PET and Bicalutamide in Metastatic Breast Cancer
University Medical Center Groningen
Phase 2 Completed
NCT00528866 2019-04-24
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Radiation Therapy Oncology Group
Phase 2 Completed
NCT01664923 2019-01-30
STRIVE
Pfizer
Phase 2 Completed
NCT00298155 2018-08-09
TAPS
University of Washington
Phase 2 Completed
NCT00283803 2018-08-07
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
University of Washington
Phase 2 Completed
NCT00165399 2018-06-25
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01120236 2018-02-26
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00814788 2018-01-10
UCDCC#215
University of California, Davis
Phase 2 Completed
NCT00630344 2017-12-08
RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00589472 2017-10-06
TARGET
National Cancer Institute (NCI)
Phase 2 Completed
NCT00658697 2017-05-25
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00486642 2017-05-24
Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00170157 2017-05-15
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT00769795 2017-03-29
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
University of Washington
Phase 2 Completed
NCT00659438 2016-12-05
Efficacy and Safety of Zactimaâ„¢ in Patients With Castration-refractory Metastatic Prostate Cancer
Sanofi
Phase 2 Completed
NCT00776594 2016-10-21
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00586898 2016-03-25
Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01674270 2015-12-22
Degarelix Neo-Adjuvant Radical Prostatectomy Trial
University Health Network, Toronto
Phase 2 Completed
NCT00108732 2015-06-30
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00666666 2014-12-18
R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00349557 2014-07-16
Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
Benaroya Research Institute
Phase 2 Completed
NCT01250717 2014-02-04
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00086736 2013-11-19
Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
University of Alabama at Birmingham
Phase 2 Completed
NCT00028769 2013-07-16
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00012090 2013-06-18
Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00757692 2013-02-20
Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.
British Columbia Cancer Agency
Phase 2 Completed
NCT00684905 2012-11-12
Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy
Mayo Clinic
Phase 2 Completed
NCT00637871 2011-01-24
Casodex - Nolvadex Combination
AstraZeneca
Phase 2 Completed
NCT00418080 2007-10-08
Survival Outcomes and Tumor Molecular Profile Following Bicalutamide Neoadjuvant Therapy
University of L'Aquila
Phase 2 Completed